Patents by Inventor David C. Remy

David C. Remy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of Akt activity
    Patent number: 7034026
    Abstract: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: April 25, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Stanley F. Barnett, Samuel L. Graham, David C. Remy
  • Inhibitors of akt activity
    Publication number: 20040143117
    Abstract: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: October 2, 2003
    Publication date: July 22, 2004
    Inventors: Stanley F. Barnett, Samuel L. Graham, David C. Remy
  • Nitrogen-containing spirocycles
    Patent number: 5698566
    Abstract: A series of novel spirocycles of general structural formula: ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form thereof are presented, whereinR.sup.1 =H.sub.3 CSO.sub.2 NH--, H.sub.3 CO--, alkylSO.sub.2 --, alkylCONH--, NO.sub.2 --;R.sup.2 =H, --OCH.sub.3 ;R.sup.3 and R.sup.4 taken together are .dbd.O, or R.sup.3 is H and R.sup.4 is OH;R.sup.5 =R.sup.6 taken together are --CH.sub.2 --CH.sub.2 --, .dbd.CH.sub.2 ;R.sup.7 is ##STR2## which are Class III antiarrhythmic agents and positive inotropic or cardiotonic agents.
    Type: Grant
    Filed: November 2, 1995
    Date of Patent: December 16, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Benzodiazepines
    Patent number: 5679672
    Abstract: Compounds of structures (I) and (Ia) are Class III antiarrhythmic agents ##STR1##
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: October 21, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Nitrogen-containing spirocycles
    Patent number: 5633247
    Abstract: Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.
    Type: Grant
    Filed: July 5, 1995
    Date of Patent: May 27, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Antiarrhythmic benzodiazepines
    Patent number: 5595990
    Abstract: Benzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: January 21, 1997
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Furanodiazepines
    Patent number: 5453424
    Abstract: This invention is concerned with novel compounds represented by structural formulae I and II. ##STR1## which are useful in the treatment of cardiac arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: September 26, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Gerald S. Ponticello, John J. Baldwin, David C. Remy
  • Antiarrhythmic benzodiazepines
    Patent number: 5439906
    Abstract: Imidazobenzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: August 8, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Robert M. DiPardo, Roger M. Freidinger, John J. Baldwin, David C. Remy
  • Antiarrhythmic benzodiazepines
    Patent number: 5438055
    Abstract: Benzodiazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: August 1, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jason M. Elliott, David A. Claremon, Nigel Liverton, David C. Remy, Harold G. Selnick
  • 3-acylaminobenzodiazepines
    Patent number: 5428157
    Abstract: 3-Acylamino-5-Aminobenzo[1,5]diazepines are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: June 27, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Antiarrhythmic benzodiazepines
    Patent number: 5426185
    Abstract: Benzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: June 20, 1995
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Nigel Liverton, David C. Remy, Harold G. Selnick
  • Adjuncts in cancer chemotherapy
    Patent number: 5272159
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: December 21, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
    Patent number: 5215989
    Abstract: Compounds of structural formula: ##STR1## wherein Ar is an aromatic ring, B is a cyclic moiety fused to Ar of 5-7 members, X and Y are bridging groups, Q is a nitrogen containing heterocycle, R.sup.2 and R.sup.3 are H, substituted or unsubtituted C.sub.1-3 alkyl, C.sub.1-3 alkoxy, N(R).sub.2, halogen, CF.sub.3 or R.sup.5 and R.sup.1 is H or an aryl group.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: June 1, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David A. Claremon, Jason M. Elliott, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Nitrogen-containing spirocycles
    Patent number: 5206240
    Abstract: Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.
    Type: Grant
    Filed: June 3, 1991
    Date of Patent: April 27, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Jason M. Elliott, David A. Claremon, Gerald S. Ponticello, David C. Remy, Harold G. Selnick
  • Methods for thrombolytic therapy
    Patent number: 5188830
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 2, 1990
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Atkinson, David A. Claremon, John J. Baldwin, Paul A. Friedman, David C. Remy, Andrew M. Stern
  • Medicinal use of certain tetrazolium salts
    Patent number: 5177092
    Abstract: Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • Imidazole compounds in compositions and methods in thrombolytic therapy
    Patent number: 5152988
    Abstract: The use of imidazoles of the formula ##STR1## and imidazolium salts of the formula ##STR2## in thromobolytic therapy are described.
    Type: Grant
    Filed: February 20, 1991
    Date of Patent: October 6, 1992
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, David C. Remy, John J. Baldwin
  • Adjuncts in cancer chemotherapy
    Patent number: 5114919
    Abstract: Various cyproheptadine derivatives sensitize multidrug resistant cells to certain chemotherapeutic agents. As such, these cyproheptadine derivatives are useful as adjuncts in the reversal of multidrug resistance in mammalian tumor cells either as compounds, pharmaceutically acceptable salts, or pharmaceutical composition ingredients in combination with anticancer chemotherapeutic agents or compounds.
    Type: Grant
    Filed: February 11, 1991
    Date of Patent: May 19, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy
  • Benzofuran compounds as class III antiarrhythmic agents
    Patent number: 5112824
    Abstract: Compounds of structural formula: ##STR1## wherein R' is hydrogen or an aromatic ring system, and Q is a substituted nitrogen or a nitrogen containing heterocycle, X and Y are bridging groups and p is 0 or 1, and E is --S-- or --O--, are Class III antiarrhythmic agents.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: May 12, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Harold G. Selnick, Gerald S. Ponticello, David C. Remy, David A. Claremon, Jason M. Elliott
  • Imidazole compounds and their use as transglutaminase inhibitors
    Patent number: 5098707
    Abstract: Compositions useful for thrombolytic therapy comprising a plasminogen activator such as tPA or streptokinase together with an imidazolium salt having the formula ##STR1## in a pharmaceutically acceptable carrier and methods for inhibiting hard clot formation or supplementing fibrinolytic therapy are described. The imidazolium salt also may be used with a platelet aggregation inhibitor or anticoagulant.
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: March 24, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon